Therapeutic plasma exchange for children treated at Sohag University Hospital
Official title: Experience With Therapeutic Plasma Exchange in the Pediatric Nephrology Unit of Sohag University Hospital
Run by Sohag University · NCT07158463 · Data updated 2026-11-12
See if therapeutic plasma exchange (TPE) is safe and effective for children treated at Sohag University Hospital by documenting who receives it, how it is done, and what outcomes and complications occur.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 1 Year to 18 Years |
| Sex | All |
| Enrollment | 25 (estimated) |
| Sponsor | Sohag University Academic / other |
| Locations | 1 site (Sohag) |
| Status | Recruiting |
| Started | August 15, 2025 |
| Main results expected | August 1, 2026 |
| Study ends | August 15, 2026 |
| Registry record updated | September 5, 2025 |
| Trial ID | NCT07158463 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children aged 1–18 years treated at Sohag University who undergo or are candidates for TPE and who can tolerate central line placement, are hemodynamically stable, and have no allergy to plasma products.
✕Probably not a fit
Children who are hemodynamically unstable, actively septic, unable to tolerate central line placement, or allergic to fresh frozen plasma or albumin would be excluded and unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational review of all pediatric patients (ages 1–18) who underwent therapeutic plasma exchange (TPE) in the Pediatric Nephrology Unit at Sohag University Hospital. Clinical data will be collected on indications for TPE, the procedures used (including vascular access and replacement fluids), immediate and short-term outcomes, and any complications. Results will be compared with national and international reports to identify opportunities for improvement and standardization. Patients unable to tolerate central line placement, who are septic or hemodynamically unstable, or who have allergies to FFP or albumin are excluded.
Why it matters
Potential benefit: If successful, the findings could help standardize TPE protocols and improve safety and outcomes for pediatric nephrology patients at Sohag and similar centers.
How similar studies have gone: Numerous national and international reports show TPE can be safe and beneficial in selected pediatric nephrology cases, although practices and outcomes vary by center.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: All pediatric patients (aged 1-18 years) who underwent TPE during the study period. Both male and female. Exclusion Criteria: Patients who cannot tolerate central line placement Patients who are in an actively septic state or are hemodynamically unstable . Patients who have allergies to fresh frozen plasma (FFP) or albumin, depending on the type of plasma exchange
Where it's running
-
Faculty of medicine sohag university
Sohag, Egypt Recruiting
Study contacts
- Study coordinator: Shohanda Ahmed Mohamed, Master degree
- Email: shohandaahmed12345@gmail.com
- Phone: 01228288470
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.